TACSTD2 and breast carcinoma: In addition to other TNBC and HR+/HER2- breast cancer populations, sacituzumab govitecan is undergoing evaluation in a range of tumor types where TROP2 is highly expressed, including lung cancers, head and neck cancer and gynecological cancer studies.